Cargando…

Bevacizumab in the therapy for refractory metastatic colorectal cancer

Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in t...

Descripción completa

Detalles Bibliográficos
Autor principal: Mulcahy, Mary F
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727788/
https://www.ncbi.nlm.nih.gov/pubmed/19707427